¸Ã¶àÖÐÐÄÑо¿ÏîÄ¿ÓÉÉϺ£½»Í¨´óѧҽѧԺÁ¥ÊôÈð½ðÒ½ÔºÉñ¾ÄÚ¿ÆÍŶÓǣͷ£¬Õã½´óѧҽѧԺÁ¥ÊôµÚ¶þÒ½Ôº¡¢Õã½Ê¡Ì¨ÖÝÒ½Ôº¡¢¸´µ©´óѧÁ¥Êô»ª¶«Ò½Ôº¡¢º¼ÖÝÊеÚÒ»ÈËÃñÒ½Ôº¡¢¼ÎÐË´óѧÁ¥ÊôµÚ¶þÒ½Ôº¡¢°ö²ºÒ½¿Æ´óѧµÚÒ»Á¥ÊôÒ½Ôº¡¢ÓÀ¿µÊеÚÒ»ÈËÃñÒ½Ôº¡¢ÓÀ¿µÊÐÖÐÒ½Ôº¡¢ÉϺ£ÊеÚÒ»ÈËÃñÒ½ÔºµÈ¾ÅËùÒ½ÔºÅäºÏ¼ÓÈë¡£
ÂÛÎÄÐû²¼½Øͼ
¿¹DPPXÄÔÑ×ÊÇз¢Ã÷µÄ½ÏÓÐÊýµÄ×ÔÉíÃâÒßÐÔÄÔÑ×£¬ÓÉBoronat¼´ÊÇ2013ÄêÂÊÏȱ¨¸æ[2]£¬Èð½ðÒ½ÔºÓÚ2019Ä걨¸æÎÒ¹ú»¼Õß[3,4]¡£DPPXÊÇÒ»ÖÖ¼ØͨµÀKv4.2Ñǵ¥Î»µ÷ÀíÂÑ°×£¬ÆÕ±éÂþÑÜÓÚÖÐÊàÉñ¾ÏµÍ³Éñ¾Ôª°ûÌåºÍÊ÷Í»£¬»¹ÂþÑÜÓÚ³¦µÀÉñ¾½ÚÖС£¸Ã¿¹ÌåÀàÐÍÄÔÑ׵䷶ÌåÏÖ³ýÖÐÊàÉñ¾ÏµÍ³Ì«¹ýÐË·Ü¡¢ÈÏÖª/¾«ÉñÕÏ°Í⣬»¹»áÓи¹Í´¡¢¸¹ÐººÍÌåÖؼõÇáµÈ¶àÖÖÖ¢×´[4]¡£
Ñо¿ÄÚÈÝ
¸ÃÑо¿ÍøÂç²¢ÆÊÎöÁË2021Äê3ÔÂÖÁ2023Äê6ÔÂʱ´ú¾ÍÕïµÄ14Ãû»¼ÕßµÄÁÙ´²Ö¢×´¡¢¿¹ÌåЧ¹û¡¢Ó°ÏñÐÅÏ¢ºÍÖÎÁÆÔ¤ºóµÈÐÅÏ¢¡£Ñо¿·¢Ã÷£º¿¹DPPXÄÔÑ×»¼ÕßµÄÖÐλÄêËêΪ46Ë꣨11~72Ë꣩£¬ÄÐÐÔÕ¼´ó¶¼£¨9/14£©¡£Ö÷ÒªÖ¢×´°üÀ¨ÈÏÖªÕÏ°£¨7/14£©£»ÖÐÊàÉñ¾ÏµÍ³ÐË·Ü·ÜÐÔ£¨6/14£©£¬È磺¼¡ÕóÂΡ¢ñ²ðﱬ·¢ºÍÖ«Ìå³é´¤£»Î¸³¦¹¦Ð§ÕÏ°£¨5/14£©£»¾«ÉñÕÏ°£¨5/14£©£¬È磺»Ã¾õºÍ¾«ÉñÐÐΪÒì³£¡£Í¬Ê±Ò²·¢Ã÷¸ü²»³£¼ûµÄÖ¢×´£ºË¯ÃßÕÏ°£¨2/14£©£¬ÑÓËè×ÛºÏÕ÷£¨1/14£©£¬ñ²ð2/14£©¡£
·ºÆðË«ÖØ¿¹Éñ¾Ôª¿¹ÌåÑôÐÔ
ÓÐ2Ãû»¼Õß·ºÆðDPPX¿¹ÌåÓëÆäËû×ÔÉíÃâÒß¿¹Ìå¹²´æ¡£ÆäÖл¼Õß13µÄѪÇ忹DPPX¿¹ÌåºÍ¿¹NMDAR¿¹Ìå¾ù³ÊÑôÐÔ£¬µÎ¶È»®·ÖΪ1£º100ºÍ1£º32£¬Ö÷Ҫ֢״Ϊ¸¹Ðº¡¢¼¡Èâ¾·ÂΡ¢¸ÐÊÜÒì³£µÈ¡£ÆäÇкϿ¹DPPXÄÔÑ×ÌØÕ÷ÐÔÌåÏÖ£¬ÇÒDPPX¿¹ÌåµÎ¶È¸ü¸ß£¬Ë¼Á¿Õï¶ÏÆäΪ¿¹DPPXÄÔÑס£Ë«ÖØ¿¹Éñ¾Ôª¿¹ÌåÑôÐÔAE£¬»¼ÕßµÄÁÙ´²ÌåÏÖ¡¢Ö²¡»úÖÆ¡¢¶ÔÖÎÁƵķ´Ó¦¾ù¿ÉÄܱ¬·¢×ª±ä¡£Òò´Ë£¬Ó¦¾ÙÐÐÏà¹ØÉñ¾Ôª¿¹ÌåµÄÖÜȫɸ²é£¬¾¡¿ìÃ÷È·Õï¶Ï¡£
Ó°ÏñѧÌØÕ÷
42.9%µÄ»¼ÕßÓÐMRIÒì³££¬°üÀ¨Æ¤ÖÊÔöÇ¿¡¢°×Öʸı䡢º£ÂíÖ×ÕÍ»òήËõÒÔ¼°Ð¡ÄÔήËõ¡£2Àý»¼Õß18F-FDG PET/MRIÌåÏÖΪò¨Ò¶¼°ÇðÄԵʹúл£¬Ó뻼ÕßÁÙ´²Ö¢×´Ò»Ö¡£¿¹DPPX¿¹ÌåÄÔÑ×»¼ÕßMRI¶àÎÞÌØÒìÐÔ [5]£¬18F¡ªFDG PET¶ÔÃ÷È·¿¹DPPX¿¹ÌåÄÔÑ×ÂÄÚ´úлģʽ¡¢Ìá¸ßÑôÐÔ¼ì³öÂÊ¿ÉÄÜÓÐËù×ÊÖú[2]¡£
¿¹DPPXÄÔÑ×»¼ÕßµÄÉñ¾Ó°ÏñѧÌåÏÖ¡£(A£¬B)12ÀýÈÏÖªÕÏ°»¼ÕߴŹ²Õñ³ÉÏñ(MRI)ÏÔʾ×ó²àº£ÂíήËõ£¬Õýµç×Ó·¢Éä¶Ï²ãɨÃèÏÔʾ×ó²àº£Âí18F-·úÍÑÑõÆÏÌÑÌÇ(FDG)ÉãÈ¡ïÔÌ(Õýµç×Ó·¢Éä¶Ï²ãɨÃè)/ºË´Å¹²Õñ³ÉÏñ¡£13ÀýÈÏÖª¹¦Ð§ÕÏ°»¼ÕßÔÚPET/MRI¹Ú״λ(E£¬F)ÖáλºÍʸ״λ(G£¬H)ÏÔʾ˫²àò¨Ò¶1¡ãF-FDGÉãÈ¡ïÔÌ¡£(1,J)¹²¼Ãʧµ÷»¼Õß14ÀýMRIÏÔʾСÄÔήËõ¡£
ѪÇå¼°ÄÔ¼¹ÒºÖÐDPPX¿¹Ìå¼ì²â³ÊÑôÐÔ¡£(A) CBA·¨-»¼ÕßѪÇå¼°ÄÔ¼¹ÒºÑù±¾¼ì²âÓ«¹âЧ¹ûͼ£»(B) TBA-»ùÓÚº£Âí¡¢Ð¡ÄÔ×éÖ¯ÇÐƬӫ¹âЧ¹ûͼ¡£
Ñо¿Ð¡½á
Éñ¾ÏµÍ³ºÍÃâÒßϵͳ֮¼ä´í×ÛÖØ´óµÄÏ໥×÷ÓÃÉ漰ϸÃܵÄÐźÅת´ï¡¢Ï¸°ûǨáãºÍÃâÒßµ÷ÀíÀú³Ì£¬ÓÕ·¢µÄÁÙ´²ÌåÏÖ¸üÊǶàÑùÐÔÇÒ·ÇÌØÒìÐÔ¡£mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾Ó뺣ÄÚÉñ¾¿Æѧר¼ÒµÄÐÂÑо¿£¬Îª¿¹DPPXÄÔÑ×µÄÁÙ´²ÌØÕ÷ÌṩÁËеĿÆѧ֤¾Ý£¬Íƶ¯Á˾«×¼Ò½ÁƵÄÇ°½ø¡£
mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾Éñ¾&ÃâÒß¼²²¡ÖÐÐÄרעÓÚÉñ¾ÏµÍ³¼²²¡µÄ¼ì²âÊÖÒÕÁ¢Òì¡¢ÏîÄ¿·õ»¯¼°ÁÙ´²Ó¦Óá£ÒÀÍнṹÌìϵÄÁ¬Ëø»¯Ò½Ñ§ÊµÑéÊҺͿçÇøÓòר¿ÆͬÃ˵ÄÓÅÊÆ£¬¸ÃÖÐÐĽô¸ú¿¹Ìå¼ì²â¿Æ¼¼Ç°ÑØ£¬ÀýÈçÍƳöMOG-IgG»îϸ°û¼ì²â·¨£¬×ÛºÏÉñÃâ¼ì²âÊÖÒÕƽ̨£¬ÒÑÀÖ³ÉÅбð³öÉÏ°ÙÖÖÓÐÊý¿¹Éñ¾Ôª¿¹Ì壬Ϊ̽Ë÷δ֪µÄÐÂÐÍ¿¹Ìå¡¢¿ªÕ¹´ó¹æÄ£Éñ¾ÃâÒß¼²²¡Ñо¿µÓÚ¨Á˼áʵµÄÊý¾Ý»ùʯ¡£
ÒÀ¸½¸»ºñµÄ¼ì²â·þÎñÓëʵÑéÊÒÔËÓªÂÄÀú£¬mg±ùÇòÍ»ÆƹÙÍøÍøÕ¾ÕýÒ»Á¬Íƶ¯Éñ¾¼²²¡Õï¶ÏÁ÷³ÌµÄ±ê×¼»¯Àú³Ì£¬ÌáÉýÐÐÒµ·þÎñˮƽ¡£
²Î¿¼ÎÄÏ×
[1] Gao Y, Zhang Y, Chunyu H, et al. Expanding the clinical spectrum of anti-DPPX encephalitis: a multicenter retrospective study. Front. Neurosci. 18:1379933.
[2] Boronat A, Gelfand JM, GresaArribas N, et al. Encephalitis and antibodies to dipeptidylpeptidaselike protein6, a subunit of Kv4.2 potassium channels[J]. Ann Neurol, 2013, 73(1): 120128.
[3] Zhou Q, Zhu X, Meng H, et al. Anti-dipeptidyl-peptidase-like protein 6 encephalitis, a rare cause of reversible rapid progressive dementia and insomnia. J Neuroimmunol. 2020 Feb 15;339:577114.
[4] ÖÜÇÚÃ÷,²ÌÓÂ,ÄßÓÅ,µÈ. ¿¹¶þëÄ»ùëÄøÑùÂÑ°×-6¿¹ÌåÄÔÑ×[J].ÖйúÏÖ´úÉñ¾¼²²¡ÔÓÖ¾,2020,20(10):862-867.
[5] ÖлªÒ½Ñ§»áÉñ¾²¡Ñ§·Ö»áÉñ¾Ñ¬È¾ÐÔ¼²²¡ÓëÄÔ¼¹ÒºÏ¸°ûѧѧ×é. Öйú×ÔÉíÃâÒßÐÔÄÔÑ×ÕïÖÎר¼Ò¹²Ê¶£¨2022Äê°æ£©[J]. ÖлªÉñ¾¿ÆÔÓÖ¾, 2022, 55(9): 931-949.
[6] Hara, M., Ari?o, H., Petit-Pedrol, M., et al. DPPX antibody-associated encephalitis: Main syndrome and antibody effects. Neurology 88, 1340¨C1348.